Search

Ottavio N Arancio

from New York, NY
Age ~67
Get Report
Also known as:
Arancio Ottavio
Phone and address:
2700 Broadway APT 5H, New York, NY 10025
Related to:
Giuseppina Arancio, 65
Connected to:
Brian Arancio, 44Joseph M Arancio, 63Angel Arancivia, 42Jared M Arand, 39Jason R Arand, 48Jerome C Arand, 50Adriana Aranda, 45Alba Aranda, 41Allen J Aranda, 36Americo A Aranda, 42

Ottavio Arancio Phones & Addresses

  • 2700 Broadway APT 5H, New York, NY 10025
  • 160 48Th St, New York, NY 10017
  • 601 113Th St, New York, NY 10025 (212) 666-1337

Work

Company: Columbia university Position: Md, phd

Industries

Research

Resumes

Resumes

Ottavio Arancio Photo 1

Md, Phd

View page
Location:
New York, NY
Industry:
Research
Work:
Columbia University
md, phd

Business Records

Name / Title
Company / Classification
Phones & Addresses
Ottavio Arancio
Owner
Citta Pharmaceuticals
Commercial Physical Research
2700 Broadway, New York, NY 10025

Publications

Us Patents

Cell Cultures From Animal Models Of Alzheimer's Disease For Screening And Testing Drug Efficacy

View page
US Patent:
20050172344, Aug 4, 2005
Filed:
Nov 3, 2004
Appl. No.:
10/980922
Inventors:
Ottavio Arancio - New York NY, US
Paul Mathews - Irvington NY, US
Stephen Schmidt - Nutley NJ, US
Ralph Nixon - Tarrytown NY, US
Fortunato Battaglia - New York NY, US
Fabrizio Trinchese - Rome, IT
Shumin Liu - Tappan NY, US
International Classification:
A01K067/027
C12N005/06
US Classification:
800012000, 435354000
Abstract:
The present invention describes a dissociated cell culture system comprising cells of the hippocampus, one of the brain areas affected by Alzheimer's Disease (AD) or amyloid beta-related diseases. This culture system comprises hippocampal neuronal and glial cells from animal models of AD, particularly, but not limited to, double transgenic mice expressing both the human APP mutation (K670N:M671L) (mAPP), and the human PS1 mutation (M146L) (mPS1), and serves as a powerful tool for the screening and testing of compounds and substances, e.g., drugs, for their ability to affect, treat, or prevent AD or β-amyloid-related diseases. The effects of a test substance on the cells in this culture system can be quantitatively assessed to determine if the test substance affects the cells biochemically and/or electrophysiologically, and/or optically, and/or immunocytochemically. The present in vitro culture system is advantageous for AD drug screening, because it is rapid and efficient. By contrast, even in the fastest animal model of AD, pathology does not start before the end of the second month. If such in vivo animal models are used, it is necessary to wait at least the two month time duration or longer to test for drug efficacy for AD treatment or prevention. At the same time the present invention provides a tool for production of amyloid-beta that can be used for electrophysiological, behavioral, and toxicological studies.

Methods For Increasing Learning And Memory In Amyloid-Beta-Related Neurodegenerative Disorders By Increasing Uch-L1 Activity And Methods For Identifying Enhancers Of Uch-L1 Activity

View page
US Patent:
20070071724, Mar 29, 2007
Filed:
Jun 29, 2006
Appl. No.:
11/477771
Inventors:
Ottavio Arancio - New York NY, US
Michael Shelanski - Brooklyn NY, US
Bing Gong - Fort Lee NJ, US
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
International Classification:
A61K 48/00
C12Q 1/68
G01N 33/53
C07H 21/04
C12P 21/06
C12N 9/64
US Classification:
424093200, 435006000, 435007100, 435069100, 435320100, 435325000, 435226000, 435456000, 536023200
Abstract:
The invention is directed to methods for increasing learning and memory in a subject with a neuropathological condition, specifically a condition related to elevated beta-amyloid deposition, the method comprising administering to the subject an effective amount of a compound capable of increasing the activity of Uch-L1. The invention is also directed to screening methods for identifying compounds that enhance the activity of the proteasome system, Uch-L1, or both.

Ginkgolide Compounds, Compositions, And Extracts, And Uses Thereof

View page
US Patent:
20090156668, Jun 18, 2009
Filed:
Mar 21, 2005
Appl. No.:
10/593427
Inventors:
Ottavio V. Vitolo - Cambridge MA, US
Koji Nakanishi - New York NY, US
Michael L. Shelanski - Brooklyn NY, US
Sonja Krane - Del Mar CA, US
Ottavio Arancio - New York NY, US
Stanislav Jaracz - Trinec, CZ
Nina D. Berova - New York NY, US
Assignee:
The Trustees Of Columbia University In The City Of New York - New York NY
International Classification:
A61K 31/365
C07D 493/22
A61K 51/00
C12N 5/02
US Classification:
514462, 549265, 424 165, 435375
Abstract:
The present invention relates to Ginkgolide derivatives, compositions and extracts comprising one or more Ginkgolides and/or derivatives thereof and methods of use of the compositions to treat neurological disorders and as imaging agents.

Methods For Treating Mild Cognitive Impairment

View page
US Patent:
20090298864, Dec 3, 2009
Filed:
Apr 7, 2006
Appl. No.:
11/918295
Inventors:
Ottavio V. Vitolo - New York NY, US
Ottavio Arancio - New York NY, US
Michael L. Shelanski - Brooklyn NY, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
A61K 31/435
A61K 31/4353
A61K 31/4015
A61P 25/28
US Classification:
514297, 514319, 514424
Abstract:
The present invention relates to compounds, compositions, and methods useful for: (i) treating or preventing mild cognitive impairment, or (ii) delaying the progression from mild cognitive impairment to Alzheimer's disease in a subject in need thereof.

Methods And Compositions For Enhancing Memory

View page
US Patent:
20100081613, Apr 1, 2010
Filed:
Mar 30, 2009
Appl. No.:
12/414160
Inventors:
Ottavio Arancio - New York NY, US
Daniela Puzzo - Catania, IT
Cristina Alberini - New York NY, US
Paul Mathews - Irvington NY, US
Assignee:
THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK - New York NY
International Classification:
A61K 38/16
A61P 25/00
A61P 25/28
A61P 25/16
US Classification:
514 12
Abstract:
The invention is directed to methods for enhancing memory by administering low doses of beta amyloid peptide. The invention also encompasses methods for increasing synaptic plasticity in a subject which comprises administering to the subject low doses of beta amyloid peptide.

Tau Protein Screening Assay

View page
US Patent:
20110027817, Feb 3, 2011
Filed:
Mar 8, 2010
Appl. No.:
12/719703
Inventors:
Ottavio Arancio - New York NY, US
Daniela Puzzo - Catania, IT
James G. Moe - Stamford CT, US
International Classification:
C12Q 1/02
G09B 19/00
US Classification:
435 29, 434236
Abstract:
This invention is directed to methods for determining if a test compound can ameliorate tau protein induced reduction of long term potentiation in a neural structure. The invention is also directed to methods for determining if a test compound can re-establish or rescue synaptic function in a neural structure following damage by tau proteins. Also encompassed by disclosures in this invention are methods to determine if a test compound can increase synaptic function in a neural structure contacted with tau proteins and methods for determining if a test compound is capable of treating Alzheimer's disease or other tauopathies in a subject.

Phosphodiesterase Inhibitors And Uses Thereof

View page
US Patent:
20120076732, Mar 29, 2012
Filed:
Jun 23, 2011
Appl. No.:
13/167540
Inventors:
Yan Feng - Shanghai, CN
Ottavio Arancio - New York NY, US
Shixian Deng - White Plains NY, US
Donald W. Landry - New York NY, US
International Classification:
A61K 31/4706
A61K 49/00
A61K 31/5025
A61P 25/00
A61K 31/519
A61K 31/4985
C07D 215/44
A61P 25/28
US Classification:
424 92, 546159, 514313, 51425216, 514250, 514248
Abstract:
The invention provides for compounds that are phosphodiesterase inhibitors. The invention further provides for a method for screening compounds that bind to and modulate a phosphosdiesterase protein. The invention also provides methods for treating conditions associated with accumulated amyloid-beta peptide deposit accumulations by administering a phosphodiesterase-binding compound to a subject.

Histone Acetyltransferase Activators And Uses Thereof

View page
US Patent:
20130121919, May 16, 2013
Filed:
Jun 11, 2012
Appl. No.:
13/493490
Inventors:
Yan FENG - Shanghai, CN
Mauro Fa - New York NY, US
Ottavio Arancio - New York NY, US
Shi Xian Deng - White Plains NY, US
Donald W. Landry - New York NY, US
Yitshak Francis - New York NY, US
Assignee:
The Trustees of Columbia University in the City of New York - New York NY
International Classification:
C07C 235/64
C07C 323/42
C07D 213/82
C07D 213/75
C12Q 1/48
C07C 237/40
C07D 239/52
C07D 333/38
A61K 49/00
C07C 323/67
C07C 235/56
US Classification:
424 92, 564 85, 564162, 514603, 514618, 564184, 514617, 564165, 514620, 564179, 514622, 546291, 514346, 546309, 514352, 564156, 544319, 514269, 549 64, 514445, 435 15, 435 71
Abstract:
The invention provides for a method for screening compounds that bind to and modulate a histone acetyltransferase protein. The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a HAT-activating compound to a subject.
Control profile
Ottavio N Arancio from New York, NY, age ~67 Get Report